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The majorityofhuman peripheral blood T lymphocytes express surface receptor
for antigen (TCR) consisting ofa disulphide-linked heterodimer with a Mr of-90
kD, which is noncovalently linked to CD3, a set of proteins displaying molecular
weight ranging between 20 and 28 kD (1, 2).
While both TCR chains, an acidic a chain (mol wt, 45-52) and a more basic Q
chain (mol wt, 37-45), contain variable andconstant region domains, the CD3 pro-
teins are invariant (3-5). Cell surface expression ofTCR-a/0 can be revealed by the
use ofmAbs such as WT31, which react with all T lymphocytes expressing TCR-
a/(3 (6). Several lines ofevidence now exist that CD3 molecules can be expressed
in association with TCR proteins different from the conventional a and R chains
(7-11). Indeed, both CD3+WT31- Tcell leukemias and T cell clones (12) derived
from immunodeficient patients have been shown to expressTCR moleculesencoded
by two different sets of rearranging genes termed y and S (13-21). Further experi-
ments performed on CD3`WT31 - populations or clones derived from normal
donors provided evidence that expression of these C133-associated proteins charac-
terize a small T lymphocyte subset displaying unique phenotypic and functional
characteristics (9, 11, 22, 23). Among TCRy/8, at least two distinct forms have been
identified (12). While the Cyl gene segment usage correlates with the expression
ofa disulphide-linked form of receptor, the usage ofthe Cy2 gene segment results
in a non-disulphide-linked form (24, 25). The recent availability ofmAbs directed
against TCR-y/S offers the possibility to directly analyze these surface proteins. In
this context, we recently selectedanmAb(termed BB3) that reacts with TCR mole-
cules expressed on approximately two thirds of peripheral CD3+WT31- lympho-
cytes(26). Another mAb termed STCS-1 has recently been selected that reacts with
the S chain of the TCR complex.
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TWO DISTINCT FORMS OF T CELL RECEPTOR Y/S
By using these two mAbs, we analyzed a large panel of CD3 + WT31 - clones. We
show that ti 100 % of such clones were reactive with one or another mAb. More im-
portantly, BB3' clones failed to react with STCS-1 mAb, and, conversely, those
stained by STCS-1 did not react with BB3 mAb. The mutually exclusive expression
of the antigenic determinants recognized by the two antibodies was further confirmed
by functional experiments in which triggering of the lytic machinery of BB3+ or
S-TCS-1 + clones only occurred in the presence of the appropriate mAb. Biochem-
ical analyses revealed important differences in the TCR molecules immunoprecipi-
tated from the two types of clones. BB3-reactive CD3+ WT31- clones only expressed
the disulphide-linked form of TCR, whereas STCS-1 + clones expressed the non-
disulphide-linked form of TCR. In addition, two-dimensional (2D)'-PAGE analysis
revealed major differences in the charge mobility of TCR chains immunoprecipi-
tated from the two types of clones.
Materials and Methods
Cloning ofCD3` WT31 - PBL.
￿
PBL were isolated from seven different normal volunteers.
CD3' WT31 - lymphocytes were then isolated and cloned under limiting dilution as previ-
ously described (9, 27). Briefly, cells were cultured at various cell concentrations per well
in round-bottomed wells (Greiner Labor Technik, Nurtinger, Federal Republic ofGermany)
in the presence of irradiated feeder cells(5,000 rad) in RPMI 1640 medium containing 10%
FCS (Gibco Laboratories, Grand Island, NY), 0.5% vol/vol PHA, and an exogenous source
of IL-2 derived from PHA-stimulated human spleen cell suspensions (27). Microcultures
were considered as clones on the basis of the frequency ofproliferating microcultu're in each
experiment (28). Clones were screened directly by FRCS analysis for the presence of surface
CD3 and the simultaneous lack of reactivity with WT31 mAb. Clones were then expanded
in the presence of rIL-2 (Cetus Corp., Emeryville, CA) and in the absence of feeder cells
always in the same type of microtiter plates.
Isolation of Thymocytes.
￿
Single cell suspensions were obtained from normal thymus frag-
ments that had been removed from children (<5 yr old) during corrective cardiac surgery.
Thymocytes were isolated by teasing the thymus fragments in RPMI 1640 supplemented
with 10% FCS. Viable mononuclear cells were obtained by Ficoll/Hypaque (Pharmacia Fine
Chemicals, Uppsala, Sweden) density gradient centrifugation. For the isolation of cell sub-
populations, thymocyteswere then incubated with saturating amounts ofanti-CD4 plus anti-
CD8 antibodies for 30 min at 4°C, followed by an additional 45 min at 37°C with 1/3 dilution
ofnoncytotoxic rabbit complement(Rabbit complement-MA; Cederlane Laboratories, On-
tario, Canada).
mAbs.
￿
The mAbs used in these studies were represented by JT3A (29) and anti-Leu-4
(anti-CD3) (Beckton Dickinson and Co., Basel, Switzerland), B9.4 (anti-CD8) (30), CK7.9
(anti-CD4) (9), WT31 (directed against the TCR complex expressed by TCR-a/p-bearing
cells) (6), BB3 directed to -60-70% of CD3' WT31 - cells (26), S-TCS-1 directed to the S
chain of CD3' WT31 - lymphocytes (T cell Sciences Inc., Cambridge, MA), MAR 21 (anti-
CD7) (29) MAR 199 (anti-HLA-DR), CD2-1, and CD2-9, which recognize distinct epitopes
of the CD2 molecule and, when used in combination, are able to induce T cell activation
(29, 31).
Flow CytofluorometricAnalyais.
￿
The techniques used have been described in detail elsewhere
(5, 29). Briefly, aliquots of 105 cloned cells were stained with the appropriate mAb followed
by fluoresceinated goat anti-mouse Ig. Control aliquots were stained with the fluorescent
reagent clone. All samples were then analyzed on a flow cytometer (FAGS II; Becton Dick-
1 Abbreviations used in this paper: NEPHGE, nonequilibrium pH gradient electrophoresis; 2D, two
dimensional.BOTTINO ET AL.
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inson Immunocytometry Systems, Mountain View, CA) gated to exclude nonviable cells.
Results are expressed as arbitrary normalized fluorescence histograms, i.e., number of cells
vs. fluorescence intensity.
Cytolytic Assays.
￿
The ability of various mAbs to trigger the cytolytic activity of clonal T
lymphocytes was assessed in a 4-h "Cr-release assay in which target cells were represented
by the murine mastocytoma cell line termed P815 (28, 32). In this assay, 5 x 103 s1Cr-labeled
P815 cells were added to each well containing 5 x 103 effector cells (for a final E/T ratio of
1 :1) in the presence of either one of the following mAbs: anti-CD3 (JT3A) (10 Al of culture
supernatant), BB3 (10 pl ofculture supernatant), S-TCS-1 (10 pl of 1 :200 dilution ofthe stock
solution) WT31 (10 pl of a 1 :50 dilution of the stock solution), and CD2-1 + CD2-9 (50
pl of a 1 :1 mixture of the two culture supernatants). The final culture volume was 200 pl
for each well. After a 4-h culture period, 100 pl was collected from each well and counted
in a gamma counter for "Cr release. Percent-specific 51Cr-release was calculated as previ-
ously described (27, 28).
Characterization ofRadioiodinated Cell Surface Proteins.
￿
Cloned cells (-1.5 x 106) were washed
five times in cold RPMI 1640, twice in PBS, and then surface-labeled with 1251 using the
lactoperoxidase/glucose oxidase-catalyzed iodination (33). After labeling, cells were washed
once in PBS and resuspended at OOC for 30 min in lysisbuffer. The lysisbuffer was as follows:
10 mM Tris HCl (pH 7.5), 0.15 M NaCl, 1 mM EDTA, and 0.02% NaN3 and contained
1 % NP40 ordigitonin. Digitonin was added at 1 g/100 ml to the abovesolution, boiled, stirred
for 20 min, cooled, allowed to stand at room temperature for at least 4 d, and then filtered.
After spinning, the supernatants were filtered and dialyzed with PBS and then precleared
three times with 20 pl of packed protein A-sepharose beads for 2 h under rotation. Lysates
were then incubated for 2 h with 200 pl ofBB3 culture supernatant or 50 gl of a 1:10 dilution
of anti-Leu-4 mAb or STCS-1 mAb. 20 pl of packed protein A-sepharose beads were then
added and samples were incubated overnight at 4'C under rotation. The immunoprecipitate
was eluted from protein A-sepharose by boiling for 5 min in buffer containing 1% SDS in
the presence or absence of5% 2-ME and analyzed on 11% discontinuous SDS-polyacrylamide
gels (34). The nonequilbrium pH gradient electrophoresis (NEPHGE) was carried out using
pH 3.5-10 ampholines followed by 11% SDS-PAGE gels for size separation as described (12).
Results
Distribution of BB3' and S7CS-1' Cells in Peripheral Blood and Thymus.
￿
To study
the expression of the TCR-y/8 surface determinants recognized by BB3 or S-TCS-1
mAbs, we analyzed unfractionated, as well as CD4- 8- T cell populations isolated
from peripheral blood or thymus. In E-rosetting cells isolated from normal periph-
era] blood, the percentages of BB3 + cells ranged from 0.5-12%, whereas S-TCS-1'
cells were 0.2-2 .3% (in 10 different donors). In addition, in all donors, the percent
of BB3' cells exceeded that of S-TCS-1' cells. TCR-y/8-enriched populations were
obtained by treating E-rosetting cellswith anti-CD4 plus anti-CD8 mAbs and com-
plement. The resulting populations contained variable proportions (40-90%) of
CD3' cells (most of which did not react with WT31 mAb). Consistently, the sum
of the percentages of BB3' and STCS-1' cells approximated those of CD3'(WT31 -)
cells in seven different donors tested. Data from two representative donors are shown
in Table I. Moreover, in polyclonal cell lines obtained by in vitro expansion (in rIL-
2) of FAGS-purified CD3' WT31 - lymphocyte populations, the sum of the percen-
tages of BB3' and S-TCS-1' cells was -100% (data not shown). In freshly pre-
pared, unfractionated, thymocyte cell suspensions, S-TCS-1' cells were 1-5.5%,
whereas BB3' cells could not be detected in four thymuses analyzed. Purified
CD4- 8- thymocytes contained variable proportions of CD3' cells and few WT31'
cells. In these TCRy/S-enriched populations, S-TCS-1' cells approximated the per-494
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CLONE
6.6 .1
TABLE I
Reactivity of BB3 and S-TCS-1 mAbs in Unfractionated or CD4- 8- Peripheral Blood
(PB) T Lymphocytes or Thymocytes
' Cells were analyzed by flow cytofluorometry; data are presented as percent-positive cells (after
subtraction of staining with the fluorescent conjugate alone).
centages of CD3' WT31 - cells, while BB3 + cells could not be detected. Two repre-
sentative experiments are shown in Table I.
Phenotypic Analysis of T Cell Clones Derived from Peripheral Blood CD3' WT31 -
Lymphocytes. Taken together, the above data suggested that BB3 and S-TCS-1
mAbs recognized different subsets ofTCR-y/8' cells. In addition, it appeared that
BB3 + and 8-TCS-1' cells could account for most, if not all, peripheral blood
CD3' WT31 - cells. To define whether indeed BB3 and S-TCS-1 mAbs reacted with
determinants of TCRy/8 expressed by different peripheral blood T cells we ana-
lyzed a large number of CD3' WT31 - cell clones. Clones were derived by limiting
dilution from CD3' WT31 - peripheral blood populations of healthy donors, as
previously described (9, 27). Clones so obtained were screened for the expression
of WT31 and CD3 surface antigen and the contaminating WT31' clones were
discarded. 5 out of 72 CD3'WT31 - clones analyzed expressed low amounts of
CD8 surface antigen, whereas the remaining were CD4- 8- . Clones were analyzed
for their reactivity with 13133 or S-TCS-1 mAbs. Approximately 70% of the
CD3'WT31 - clones analyzed were stained by BB3 mAb; more importantly, none
of such BB3' clones reacted with S-TCS-1 mAb. S-TCS-1-reactive clones were
N30%, and none of them reacted with BB3 mAb (Fig. 1). These experiments sug-
CONTROL CD3 BB3 S-TCS-1 WT31
FLUORESCENCE INTENSITY - . .
FIGURE 1. Flow cytofluorometric
analysis of surface antigens expressed
by CD3' WT31- human Tcell clones.
Cells were stained with either one of
the following mAbs: anti-CD3, WT31,
13133, or S-TCS-1 as described in Ma-
terials andMethods. Fluorescein-con-
jugated goat anti-mouse Ig wasused as
second reagent. Note that clones 6.6.1
and 5.25.10 were stained by 13133 but
not by S-TCS-1 mAb; on the contrary,
clones 6.6.2 and 5.6.4 were stained by
S-TCS-1 but not by 13133 mAb.
Lymphocyte population Exp. CD3 WT31 BB3 S-TCS-1
Unfractionated PB E' cells 1 96` 82 12 1
2 90 85 3.5 0.5
CD4- 8- PB E' cells 1 89 3 75 8
2 68 10 45 10
Unfractionated thymocytes 1 42 40 0 3
2 46 ND 0 5 .5
CD4- 8- thymocytes 1 60 8 0 52
2 50 0 0 48BOTTINO ET AL.
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TABLE II
Appropriate Anti-receptor rnAbs Trigger the Lylic Machinery of both BB3+
and S-TCS-1* Clones
The various antibodies were added at the onset ofthe 4-h 51Cr-release assay containing the
Fc receptor-positive P815 target cells.
x Representative CD3+4-8- WT31- clones reacting with S-TCS-1 mAb or with 13133 mAb
were tested against "Cr-labeled murine target cells P815 at an E/T ratio of N1 :1.
S Data are expressed as a percent-specific 5'Cr-release.
gest that TCR surface determinants recognized by 13133 or 8-TCS-1 mAb are ex-
pressed by two distinct, non-overlapping CD3+ WT31 - lymphocyte populations. In-
terestingly, all the five CD8+ clones (derived from different donors) expressed the
8-TCS-1 determinant.
Both Types of the CD3-associated Receptors Expressed on CD3+ WT31 - T Lymphocytes Are
Functionally Active. It has been shown that mAbs directed to CD3 or TCR complex
molecules can trigger the lytic machinery of cytolytic T cells carrying the typical
a/R heterodimer (35). In addition, recent studies indicated that anti-CD3 mAbs can
also induce the cytolytic activity of CD3+WT31 - clones (36). Moreover, we showed
that all the CD3+WT31 - clones derived from normal peripheral blood display cyto-
lytic activity (37). In an attempt to define whether 11133 and 8-TCS-1 mAbs could
trigger the lytic machinery of clones expressing the corresponding antigenic deter-
minant, the same set of clones analyzed above was assessed for the ability to kill
appropriate target cells in the presence of BB3 or 8-TCS-1 mAbs. Target cells were
represented by the Fcy receptor-positive murine mastocytoma cell line P815 (32).
In Table II, we show that P815 cells were not lysed by either 13133+ or 8-TCS-l'
clones alone (that is in the absence of stimuli added) . However, both types of clones
displayed a strong cytolytic activity in the presence of PHA or anti-CD3 mAbs. On
the otherhand, antibodies to other surface molecules expressed on the effector cells
such as HLA-DR or CD7 were uneffective (not shown). Moreover, no lysis was de-
tected upon addition of WT31 mAb (this mAb triggered conventional CD3+WT31+
cytolytic clones used as control). In this cytolytic assay, 13133 mAb induced cytolytic
activity of CD3+WT31 - cells; however this effect was restricted to BB3+ clones
(Table II). Conversely, 8TSC-1 + clones were induced to kill by 8-TCS-1 but not
Clones Phenotype None
rnAb
Anti-CD3
added to
WT31
the cytolytic
BB3
test"
S-TCS-1
CD2-1
CD2-9
6 .6.2 S-TCS-1' 25 64 0 1 63 38
6 .12.4 S-TCS-1 + 0 41 0 0 36 31
6 .12.3 S-TCS-1' 0 62 1 2 63 37
5 .25.3 S-TCS-1+ 2 58 2 1 47 42
5 .25.11 S-TCS-1 + 1 73 ND 2 74 35
5 .6.4 S-TCS-1+ 5 57 4 5 55 40
6.25.4 BB3' 1 92 0 83 1 27
6.6 .1 BB3' 0 90 0 72 0 25
6.12.8 BB3* 0 82 ND 81 2 ND
5.50 .17 BB3' 3 71 2 67 4 53
5.25 .10 BB3* 3 69 0 68 3 30
5.12 .4 BB3' 2 68 ND 65 2 ND
5.25 .A WT31+ 3 62 42 2 3 38496
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FIGURE 2 .
￿
SDS-PAGE analysis ofsurface molecules im-
munoprecipitated by BB3 or S-TCS-1 mAbs from two
representative CD3'WT31 - clones. 5 x 106 cloned
cells were surface labeled with 1251 using the lactoperox-
idase technique as described in Materials and Methods .
After labeling, cells were lysed in a buffer containing
1% Nonidet P40 (NP40) . Cell lysate from clone 5.50.17
(CD3'WT31 - BB3' 8-TCS-1 - ) was immunoprecipi-
tatedwith BB3mAb under reducing(A) or nonreducing
(B) conditions, whereas cell lysate from clone 5.25 .3
(CD3'WT31 - BB3 - 8-TCS-1') was immunoprecipi-
tated with 6-TCS-1 mAb under reducing (C) or non-
reducing (D) conditions.
by BB3 mAb. These experiments further confirm that BB3 and S-TCS-1 mAbs recog-
nize antigenic determinants expressed on different subsets of CD3'WT31 - cells .
In addition, they provide direct evidence that TCR molecules recognized by the
twomAbs can transduce activation signals leading to triggering ofthe lytic machinery .
This suggests that both types of receptors are functional and may therefore partici-
pate in the complex process of antigen recognition/transduction ofthe signal, which
ultimately results in the ability of a cell to express its functional program .
Reactivity with BB3 orS-TCS-1 mAb Correlates with Different Forms of CD3-associated
TCR Structures. We next analyzed the biochemical characteristics ofTCR mole-
cules expressed in peripheral blood-derived CD3'WT31 - clones reacting with ei-
ther BB3 or S-TCS-1 mAb . To this end, cells of BB3' or S-TCS-1' clones were
surface iodinated, and molecules reactive with the corresponding antiTCR mAb
were immunoprecipitated and analyzed by SDS-PAGE . Under nonreducing con-
ditions, the BB3 mAb immunoprecipitated from BB3' clones a major 80-kD band
(and, in some cases, a minor 38-kD band) . This band, under reducing conditions,
FIGURE 3 .
￿
SDS-PAGE analysis
of CD3-associated molecules
immunoprecipitated from four
distinct CD3'WT31 - clones .
10' cloned cells were surface la-
beled and then lysed in abuffer
containing digitonin as indi-
cated in Materials and Meth-
ods . Cell lysates were then im-
munoprecipitated by using the
anti-Leu-4 (anti-CD3) mAb.
The clones analyzed in this ex-
periment were clones 6 .6 .1 and
5.25.10 (CD3'WT31 - BB3' 8-
TCS-1 - ) and clones 6 .5.4 and
5.25 .3 (CD3'WT31 -BB3 8-TCS-1' ). (A-D) C133-associated molecules were analyzed under reducing
conditions . (E-H) C133-associated molecules were analyzed under nonreducing conditions . Clone 6.6 .1
(BB3') (A and E) ; clone 5.25.10 (BB3') (B and F); clone 6 .5.4 (8-TCS-1') (C and G); clone 5.25 .3
(8-TCS-l') (D and H) .BOTTINO ET AL .
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resolved in two major components of 44 and 41 kD, respectively (and a minorcom-
ponent of 38 kD [Fig . 21) . This molecular pattern has been observed in all 13 BB3+
clones analyzed, as well as in a BB3+ polyclonal population, thus indicating that
BB3+ cells express the disulphide-linked form of theTCRy/S . In S-TCS-1-reactive
T cell clones, immunoprecipitated molecules appeared differently from those im-
munoprecipitated by BB3 mAb in BB3+ cells. Thus, both under reducing and non-
reducing conditions, a predominant diffuse band of 41-44 kD was detected, while
no high molecular weight band was present .
That cells reactive with either BB3 or 8-TCS-1 mAb express different CD3-
associated TCR molecules was further confirmed by immunoprecipitation experi-
ments using anti-CD3mAb . Under conditions that preserve the association between
CD3 andTCRmolecules (in digitonin-containing buffer) anti-CD3 mAb coprecipi-
tated from BB3+ clones a disulphide-linked form of the TCR, whereas the nondi-
sulphide-linked form was detected in immunoprecipitates from S-TCS-1 + clones
(Fig. 3) . Similar data have been obtained in all 11 S-TCS-1 + clones analyzed, thus
indicating that S-TCS-1 + cells express a nondisulphide-linked form ofTCRy/S . It
should also be noted that, under nonreducing conditions, in addition to the pre-
dominant diffuse band at 41-44 kD, a minor 38-kD band (similar to that found in
BB3' cells) was detected (Fig . 3, lanes G and H) . In most clones analyzed, how-
ever, this band could not be detected under reducing conditions, possibly because
it integrated into the major 41-44-kD band . It has been suggested that this 38-kD
band may represent the molecular product of the 8 genes (20) .
To better define the molecular differences ofTCR molecules expressed by 13133'
orS-TCS-1+ cells, we further performed immunoprecipitation experiments followed
by 2D gelelectrophoresis . In these experiments, immunoprecipitated molecules were
first separated according to their pI by NEPHGE, followed, in the second dimen-
sion, bySDS-PAGE . Fig. 4 shows themobility patternof CD3-associatedTCRmol-
ecules immunoprecipitated by anti-CD3 mAb from the BB3 + clone termed 5.25.10 .
Under reducing conditions (Fig . 4 B), two components of-38 and 41 kD displaying
a similar charge, and a third more basic 44-kD subunit could be detected . A single
FIGURE 4 .
￿
2D-PAGE analysis
oftheCD3/TCR molecular com-
plex immunoprecipitated from
the CD3'WT31 -BB3' S-
TCS-1- clone 5.25.10 . Cells
were lysedunderconditions that
preserve theCD3/TCR complex
association (buffer-containing
digitonin) andimmunoprecip-
itated with anti-Leu-4 (anti-
CD3) mAb . The CD3/TCR
complex was analyzed under
nonreducing conditions (A) and
under reducing conditions (B) .
Samples were analyzedby NEP-
GHE and, in the second dimen-
sion, 11% acrylamide gels were
used for SDS-PAGE analysis .498
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FIGURE 5 .
￿
2D-PAGE analysis
oftheCD3/TCR molecular com-
plex expressed by the
CD3'WT31 -BB3 - 6-TCS-1'
clone 6.6 .2 . Cells were labeled
with 1251 and then lysed either
in the presence of1% NP40 (A)
or in the presence of digitonin
(B) and then immunoprecipi-
tated by using the 6-TCS-1
mAb . Samples were rununder
reducing conditions .
80-kD spot displayingacharge mobility intermediate with respect to those observed
for separated chains was observed under nonreducing conditions (Fig . 4 A) .
Fig. 5 shows the2D-PAGE analysis ofCD3-associated molecules immunoprecipi-
tated from the 8-TCS-1' clone termed 6.6.2 . In Fig. 5 A, immunoprecipitation was
performed with S-TCS-1 mAb and in B with anti-Leu-4 mAb (under reducing con-
ditions) . In both cases, TCR molecules could be resolved in at least two series of
spots migrating with an apparent molwt of42-44 and of 41-43 kD, which displayed
a similar heterogeneity in charge. In addition to these two series of spots (corre-
sponding to the diffuse 41-44-kD band observed in one-dimensional SDS-PAGE),
a third series of poorly labeled spots similar in charge heterogeneity to the most
basic spots of the previous two sets was observed . This third family of spots is likely
to correspond to the 38-kD band observed in SDS-PAGE . When compared with
theTCR molecules immunoprecipitated from the BB3+ clone (Fig. 4), it was clear
that TCR molecules precipitated from the S-TCS-1' clone (Fig. 5) were more het-
erogeneous in charge, relatively more acidic and, in addition, they did not include
the very basic 44-kD spots.
To define whether the pattern displayedby theTCR molecules precipitated from
either the 5.25.10 (BB3') clone or the 6.6.2 (6-TCS-1') clone was unique (for those
two clones), or rather, it was common to all BB3' or S-TCS-I' clones, respectively,
we analyzed a large panel of clones belonging to the two phenotypic groups .
As many as 13 BB3' and 11 6-TCS-1' clones were analyzed . Fig. 6 shows the
2D-PAGE analysis (under reducing conditions) ofanti-CD3 precipitated molecules
of six representative clones (3 BB3', Fig . 6, A-C and three 6-TCS-1', D-F) . It is
evident that BB3' clones displayed very similarTCR mobility patterns as the one
shown in Fig . 4, although some differences in labeling of the 38-kD subunit was
observed . Of three 6-TCS-1' clones, two (Fig . 6D and E) displayed aTCR heter-
ogeneity pattern similar to that shown in Fig. 5 . The third clone (F) showed a rela-
tively reducednumber ofspots that correspond to the more acidic spots oftheprevious
two clones .
Discussion
In the present study, on the basis of the differential reactivity with two antiTCR-
y mAbs, we identified two distinct, nonoverlapping subsets within human periph-
eral blood CD3'WT31 - T lymphocytes . Perhaps more importantly, these subsets
express different molecular forms of CD3-associated TCR structures . Studies per-BOTTINO ET AL .
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formed both at the population and at the clonal level revealed that reactivity with
BB3 or STCS-1 was mutually exclusive, as no cells that were simultaneously stained
by the two mAbs could be identified. Since this sharp phenotypic distinction was
evident both in "resting" PBLs and inlong term cultured T cell clones, it is possible
to concludethat thedifferential expression ofthe antigenicdeterminants recognized
by the two mAbs is a stable phenotypic property of two peripheral CD3'WT31-
subsets. In addition, it is important to stress that all CD3+WT31 - clones analyzed
reacted with either antiTCR mAb. Therefore, BB3- or STCS-1-reactive cells are
likely to account for most, ifnot all, of TCR-y+ cells present in human peripheral
blood. On the other hand, only STCS-1-reactive cells could be detected within the
thymus. The lack ofBB3+ cells within the thymus could suggest that these cells may
represent an independent subset characterized by extra thymic maturation. An al-
ternative explanation could be that BB3+ cells may represent a minor subset
originating from CD3-4'8- thymocytes, which rapidly leaves the thymus upon sur-
face expression of CD3/TCR.
The mutually exclusive expression of the antigenic determinants recognized by
the two antibodies was further confirmed by experiments inwhich BB3 andS-TCS-
1 mAbwere shown to selectively triggerthe lytic machinery ofperipheral blood-de-
rived BB3+ and S-TCS-1' clones, respectively. These experiments further substan-
tiated the notion that all CD3'WT31- lymphocytes express cytolytic function, and
theyalso provideddirect evidence that the cytolyticeffector function can be induced,
in bothtypes ofclones, bystimuli acting via surfaceTCR molecules. One important
corollary ofthis finding is that both types ofTCR-y/8' lymphocytes express a func-
tionally active TCR that can transduce activation signals upon binding to the nat-
ural ligand (38). In this context, it has recently been shown that human (39), as
well as murine (40), TCR-y' cells can recognize and lyse allogenic cells in a specific
manner. This finding, together with the fact that the TCRy and -Schains are formed
by multiple rearranging genes that code for variable regions strongly supports the
concept that antigen(s) may be the natural ligand also for TCR-y+ cells.
Phenotypic analysis performed at the clonal level confirmed the finding (at the
population level) that peripheral T cells reactive with BB3 are more frequent than
S-TCS-1' cells, since BB3+ clones represented -2/3 ofall CD3'WT31- clones ana-
lyzed. In addition, all such clones expressed both CD7 and CD2 differentiation an-
tigens. With regard to the expression ofCD7, it should be mentioned that, in some
clones, the fluorescence intensity was highly reduced as compared with that detected
in conventional TCR-a/0' clones (not shown). Functional studies indicated that
CD2 surface molecules expressed by BB3' or S-TCS-1' clones transduced activa-
tion signals leadingto triggering atthelytic machinery ofthe cell (Table 11). There-
fore the "alternative" pathway ofT cell activation inititiated via surface CD2 mole-
cules appears to be expressed (and to function) in both types of TCRy' cells.
However, since both Peer- and Molt-13 leukemic cell lines, which express a non-
disulphide-linked form ofTCR and react with S-TCS-1 mAb (not shown), do not
express surface CD2 molecules, one may expect that CD2- S-TCS-1' cells may
exist. Although analysis ofa greaternumber ofclones may be required, it is noteworthy
that all of the five CD3'WT31" clones expressing CD8 antigens belonged to the
S-TCS-1' subset. Another recently described TCR-y-specific mAb (Ti-yA) (41)
reacted with both CD8- and CD8' (CD3'WT31 -) cells. According toJitsukawaBOTTINO ET AL.
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et al. (41), this mAb recognizes afraction of lymphocytes expressing thedisulphide-
linked form of TCR-f. However, if indeed CD8 is expressed only in cells bearing
the non disulphide-linked form of the TCRy, it is likely that (different from BB3)
Ti-yA mAb recognizes an antigenic determinant that is expressed also by the non
disulphide-linked form of the TCRy.
In addition to defining two cell subsets within human TCRy/S+ cells, BB3 and
S-TCS-1 mAbs identify two forms of receptors that display major molecular differ-
ences. Thus, SDS-PAGE analysis performedunder both reducing and nonreducing
conditions showed that BB3-reactive molecules are represented by disulphide-linked
heterodimers, whereas molecules immunoprecipitated by 8-TCS-1 mAbs were always
represented by the nondisulphide-linked form of the TCR-y. Previous studies pro-
vided evidence that two distinct Cy gene segments may be used by T lymphocytes
expressing the two molecular forms of TCR-y (25). Based on the amino acid se-
quences, predicted from nucleotide sequence of constant gene segments, it has been
proposed that Cyl molecular product, but not Cy2, can form interchain disulphide
bond (24, 25, 42). In fact, while Cyl encodes a cysteine residue that is found on
the NH2-terminal side ofthe presumed membrane-spanning region, in Cy2 this cys-
teineis absent. If indeed this cysteine is responsible forinterchain disulphide linkage,
only heterodimers formed by Cyl-encoded y chains would form disulphide-linked
heterodimers. In this context, preliminary experiments performed on two 8-TCS-
1+ clones (which expressed non-disulphide-linked TCR) showed the rearrangement
of Cy2 gene in both chromosomes. Studies are presently in progress to analyze Cyl
and Cy2 gene rearrangement in a panel of BB3+ or S-TCS-1' clones.
Furtherevidence for themolecular differences existing betweentheTCRexpressed
by BB3+ or 8-TCS-1+ lymphocytes was provided by 2D-PAGE analysis. Thus,
CD3-associated TCR molecules immunoprecipitated from BB3+ clones (under
reducing conditions) were represented by two proteins of 41 and 38 kD displaying
the same pl (of-6) and by a more basic (pI N7.5) 44-kD protein. A similar molec-
ular pattern in 2D-PAGE analysis has been described by Lanier et al. (11). By using
an antiserum raised againsty peptides, these authors identified the two more acidic
(38 and 41 kD) proteins as products of the TCRy genes. If this is the case, the more
basic 44-kD protein may represent the delta chain in the (BB3 +) disulphide-linked
form of TCR-y. In 8-TCS-1-reactive cells, immunoprecipitated molecules were rep-
resented by two major bands (mol wt -41-44) displaying a similar mean pI (-5.5),
both characterized by different degrees of glycosilation and by a noticeable charge
heterogeneity. The major difference between the 2D-PAGE pattern ofBB3 or 8-TCS-
1-reactive TCR molecules wasrepresented by the absence, in thelatter, of the more
basic (pI 7.5) 44-kD band. In immunoprecipitates from 6-TCS-1 + cells, under non-
reducing conditions, a 38-kD band could be detected that was no more observed
in SDS-PAGE under reducing conditions (possibly because it was integrated in the
41-44-kD band as theconsequence of a shift in the apparent molecular weight). On
the other hand, this 38-kD band could be detected in clones 6.6.2 and 5.6.4 (8-TCS-
1+) also under reducing conditions in 2D-PAGE analysis. It is noteworthy that Hata
et al. (20) showed that a similar 38-kD molecule immunoprecipitated from IDP2
cell line reacted with a mAb specific for the 8 chain. It should be noted, however,
that in the IDP2 cell line (derived from an immunodeficient patient) the 38-kD mol-
eculewas noncovalently associated to ay chain of higher molecular weight (55 kD).502
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Since the leukemic cell line termed PEER, which express a similar type of TCR
y/S, reacts with 8-TCS-1 mAb, we expected to detect at least some clones expressing
the 55-kD y chain, however none of the 11 8-TCS-1' clones (derived from seven
normal individuals analyzed so far) expressed this molecular form of the receptor.
It would be of interest to define whether also the 38-55-kD TCR heterodimer is
expressed in all normal individuals.
In conclusion, the availability of BB3 and 8-TCS-1 mAbs allows the direct assess-
ment of two subsets of TCRy' T lymphocytes characterized by the expression of
distinct molecular forms of TCR. This may be of help for defining the proportions
of these subsets in different tissues in normal and disease states and perhaps for a
better understanding of the T cell development.
Summary
Two mAbs directed to the TCR-y/8 were analyzed for their pattern of reactivity
with CD3' WT31 - cell populations or clones. In normal individuals, the BB3 mAb
reacted with -2/3 of peripheral blood CD3' WT31 - lymphocytes, whereas S-TCS-1
stained -1/3 of such cells. In addition, the sum of the percentages of BB3+ and 8-
TCS-1' cells approximated the percentages of peripheral blood CD3+WT31 - lym-
phocytes in seven normal donors tested. Also, in peripheral blood-derivedpolyclonal
CD3' WT31 - populations, cultured in IL-2, cells reacting with one or another mAb
accounted forthe whole cell population. On the otherhand, only 8-TCS-1-reactive
cells, but not BB3+ cells, could be detected in unfractionated as well as in CD4- 8-
thymocyte populations. Analysis of peripheral blood-derived CD3+WT31 - clones
showed that 70% of 72 clones analyzed reacted with BB3 mAb, but not with 8-TCS-1
mAb. On the other hand, 8-TCS-1 mAb stained the remaining BB3- clones. Five
clones expressing medium-low amounts of CD8 antigen were BB3- 8-TCS-l' .
Both types of clones lysed the Fcy receptor-bearing P815 target cell in the presence
of anti-CD3 mAb (but not of mAb directed against HLA-DR, CD7 molecules, or
TCR-a/R). In this cytolytic assay, BB3 mAb induced target cell lysis only by BB3'
clones, whereas 8-TCS-1 mAb was effective only with 8-TCS-1' clones. The C133-
associated surface molecules expressed by BB3' or 8-TCS-1' clones were analyzed
after cell surface iodination and immunoprecipitation with the corresponding anti-
TCR mAb or with anti-CD3 mAb(in digitonin-containing buffer). In SDS-PAGE,
molecules immunoprecipitated from 13 BB3' clones displayed, under nonreducing
conditions, a molecular weight of 80 kD (in some cases, a minor 38-kD band could
be detected). Under reducing conditions, two major components of 44 and 41 kD
(and a minor component of 38 kD) were detected. On the other hand, TCR mole-
cules immunoprecipitated from 11 different S-TCS-1' clones appeared as a diffuse
band of 41-44 kD, both under reducing and nonreducing conditions (under non-
reducing condition, an additional 38-kD band was present). Therefore, BB3' cells
express a disulphide-linked form of TCRy/8 whereas 8-TCS-1' cells express a
non-disulphide-linked form. TCR molecules immunoprecipitated from BB3'
clones and analyzed by two-dimensional electrophoresis were represented, under
reducing conditions, by two bands of -38 and 41 kD displaying a similar pI and
a third more basic 44 kD band. Undernonreducingconditions, BB3-reactive mole-
cules were represented by a single 80-kD band (displaying an intermediate pI withBOTTINO ET AL.
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respect to that of the reduced chains). TCR molecules immunoprecipitated from
S-TCS-1' clones were represented, in both reducing and nonreducing conditions,
by a diffuse 41-44-kD band (in which, however, two distinct components could be
detected). In addition, a poorly labeled band oflower molecular weight was present .
All these molecules displayed a similar pI and a high charge heterogeneity. Since
similar molecular patterns were consistently detected among all BB3' as well as
among all STCS-1' clones analyzed, we conclude that BB3 and STCS-1 mAbs
identify two distinct molecular forms of TCR-y/8 expressed by two different periph-
eral blood T cell subsets.
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